IP Library Granted Patent US 7,875,652
Granted Patent B2
US 7,875,652 · App. 10/466,295 · Granted Jan 25, 2011

Method and composition for treating pain or tinnitus aureum

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,875,652
App. No.
10/466,295
Granted
Jan 25, 2011
Kind
B2
Abstract

The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.

Claims (15)

1. A method of treating allodynia in a subject suffering therefrom, comprising administering to the subject an effective amount of a compound of formula (I):

wherein:

Ar is phenyl which is unsubstituted or substituted with at least one halo group;

Q is lower alkoxy containing 1-3 carbon atoms; and

Q 1 is methyl;

or a pharmaceutically acceptable salt thereof; wherein the allodynia is not related to neuropathic pain.

2. The method of claim 1 wherein the compound or pharmaceutically acceptable salt thereof is in the R configuration.

3. The method of claim 1 wherein, in the compound of formula (I), Ar is unsubstituted phenyl.

4. The method of claim 1 wherein, in the compound of formula (I), halo is fluoro.

5. The method of claim 1 wherein the compound of formula (I) is (R)-2-acetamido-N-benzyl-3-methoxypropionamide or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 wherein the subject is suffering from chronic pain.

7. The method of claim 1 wherein the subject is suffering from phantom pain.

8. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a dosage amount of about 1 mg/day to about 600 mg/day.

9. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a dosage amount of about 1 mg/day to about 300 mg/day.

10. The method of claim 8 , wherein the compound of formula (I) is administered in an oral dosage amount of about 1 mg/day to about 600 mg/day.

Assignments (3)
CORRECTIVE CHANGE OF NAME Recorded Apr 13, 2011
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 026132/0268 →
CHANGE OF NAME Recorded Feb 26, 2010
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 023985/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2003
From: SELVE, NORMA
To: SCHWARZ PHARMA AG
Reel/Frame 014732/0785 →